Herbalife (HLF) Q1 2025 Earnings Call April 30, 2025 05:30 PM ET Company Participants Erin Banyas - Vice President - Head of Investor RelationsStephan Gratziani - CEOJohn DeSimone - Chief Financial OfficerJohn Baumgartner - Managing Director, Equity ResearchRobert Rigby - AssociateHale Holden - Managing DirectorDouglas Lane - Head of Consumer Products Conference Call Participants None - Analyst Operator Good afternoon, and thank you for joining the First Quarter twenty twenty five Earnings Conference Call f ...

Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, but showed a constant currency growth of 1.4% year over year [10][27] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [28] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [11][31] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [12] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, driven by pricing actions and reduced input costs [28] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, with a 4% increase in volumes [33] - EMEA net sales were down 2% year over year on a reported basis, while up 3% on a local currency basis, with a 5% decline in volume [34] - North America saw a 4% decrease in net sales year over year, primarily due to an 8% reduction in volumes [35] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its distributor network and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in personalized health solutions [13][21] - The focus will be on innovation, operational excellence, and sustainable growth rather than just short-term gains [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][8] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [40][43] - The outlook for Q2 2025 includes expected net sales to range from down 3.5% to up 0.5% year over year, with a constant currency basis expectation of down 0.5% to up 3.5% [41][44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [39] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol? - Management indicated that it is early to discuss ROI, but the digital platform aims to support product consumption and distributor engagement [47][50] Question: What is driving the sequential decline in distributor KPIs in North America? - Management noted that the quarter started strong but faced challenges in February, with expectations for improvement in Q2 [61][63] Question: Why was the constant currency sales guidance for 2025 reduced? - The reduction was primarily due to rolling in Q1 trends, with some weakness noted in Asia Pacific and cautious expectations for China [66][67] Question: What are the intentions for Link Biosciences? - The company aims to target both athletes and a more general audience, focusing on hyper-customization in health products [71][75] Question: Is there any additional CapEx associated with the recently acquired assets? - Management confirmed that the CapEx guidance was lowered due to underspending in Q1, but future months will include necessary expenditures for the acquisitions [92][93]

Core Insights - LifeVantage Corporation successfully concluded its annual Global Convention in Salt Lake City, attended by over 2,000 Independent Consultants from around the world, focusing on business updates, product announcements, and training initiatives [1][2] Group 1: Product Launch and Expansion - The MindBody GLP-1 System™, previously available in the U.S. and Japan, is now launched for consumers in Europe, Mexico, Thailand, Australia, and New Zealand, marking a significant step in LifeVantage's global expansion [2] - Clinical study results revealed that both the MindBody GLP-1 System™ and MB System™ increased GLP-1 levels in the body by over 200 percent on average [3] Group 2: Sales Incentives and Events - The Drive ERA Q2 Sales Incentive doubles the bonus for Consultants reaching Senior Consultant 1 rank through customer enrollment and retention within the first three months [4] - LifeVantage announced the Executive Destination Trip for North American and European markets will take place in Thailand in 2026, along with the Activate Virtual Event on July 12 and the U.S. Momentum Academy scheduled for October 23-25 in Dallas, Texas [5] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, offering a range of health and wellness products designed to activate optimal health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and AXIO® nootropic energy drink mixes [6]